Company: RPTX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001193125-25-103764
Chunk: 51

Company: Repare Therapeutics Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 51
---
 Salary” for further information. |

| (2) | Amounts reflect the payment of the first 25% installment of cash retention bonuses in light of a workforce reduction implemented in August 2024. The second installment of 75% is to be paid out on May 31, 2025. |

| (3) | In accordance with SEC rules, these columns reflect the aggregate grant date fair value of the RSU and option awards granted during the periods presented computed in accordance with ASC 718 for share-based compensation transactions. Assumptions used in the calculation of these amounts are included in the notes to our audited consolidated financial statements included in our Annual Report on Form 10-K. These amounts do not reflect the actual economic value that will be realized by the named executive officer. |

36

| (4) | Reflects performance-based cash bonuses awarded to our named executive officers during the periods presented. See “—Compensation Objectives and Philosophy—Elements of Executive Compensation Program—Non-Equity Incentive Plan Compensation” for a description of the material terms of the program pursuant to which this compensation was awarded. |

| (5) | Amounts reflect for 2024: (a) for Mr. Segal, life insurance premiums in the amount of $1,774 paid by us on behalf of Mr. Segal and $11,860 in non-matching employer contributions to a retirement plan; (b) for Dr. Koehler, life insurance premiums in the amount of $458 paid by us on behalf of Dr. Koehler, and $10,350 in non-matching employer contributions to a 401(k) plan; and (c) for Dr. Zinda, life insurance premiums in the amounts of $458 paid by us on behalf of Dr. Zinda and $10,350 in non-matching employer contributions to a retirement plan. |

| (6) | Mr. Segal resigned as our President and Chief Executive Officer and as a member of our board of directors, effective April 11, 2025. Mr. Segal did not receive any additional compensation for his service as a director. |

| (7) | Dr. Koehler departed from her position as our Executive Vice President, Chief Medical Officer, effective March 31, 2025. |

Outstanding Equity Awards as of December 31, 2024 The following table sets forth certain information regarding outstanding equity awards granted to our named executive officers that remain outstanding as of December 31, 2024